Adaptimmune Therapeutics : Elliot Norry, Chief Medical Officer – SITC 2020 Surpass Presentation

Elliot Norry, CMO SITC 2020 - SURPASS poster

Disclaimer

This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and other words of similar meaning. These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 5, 2020 and our other SEC filings.

We urge you to consider these factors carefully in evaluating the forward-looking statements herein and you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements contained in this presentation speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

2

Two RECIST responses and encouraging antitumor activity

Data support future investigation of this product

Safety

Active product

Next steps

• Most adverse events were consistent with those typically experienced by cancer patients undergoing cytotoxic chemotherapy or cancer immunotherapy
• Two RECIST responses in EGJ and head and neck cancers
• Initial tumor reductions in 5 out of 6 patients
• Focus on patients with gastroesophageal, head and neck, lung, and bladder cancers based on data to-date
• Planned Phase 2 trial in gastroesophageal cancers (2021)

3 Data cut-off October 1, 2020 EGJ=esophagogastric junction cancer

BACKGROUND - SURPASS trial with ADP-A2M4CD8

A next generation SPEAR T-cell designed to improve antitumor responses

• Safety and efficacy of next-generationADP-A2M4CD8 SPEAR T-cells
• ADP-A2M4CD8co-expresses CD8α with ADP- A2M4 to increase the potency of CD4+ T-cells
• Given responses and antitumor activity observed with TCRs targeting MAGE-A4
• • Phase 2 trial in gastroesophageal cancers (2021)
  • Focusing SURPASS on enrolling patients with:
  • • Gastroesophageal cancers (gastric, esophageal, and esophagogastric)
    • Head and neck squamous cell carcinoma (HNSCC)
    • Lung cancer
    • Bladder cancer

CD4+ T-cells stabilized by CD8ɑ to enable killing while

maintaining helper function

4